Latest HER2/neu Stories
However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
NORWALK, Conn., Oct.
In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision
Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to research results released on Sunday.
Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON,
MarketOptimizer.org adds “EpiCast Report: Breast Cancer (HER2-, HER2+) – Epidemiology Forecast to 2023” to its store. Dallas, Texas (PRWEB) September 10,
Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc.
MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A.
HER3-positive circulating tumor cells home in on omentum; new target to thwart metastasis
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.